Update your browser

Your browser (Internet Explorer) is out of date.

Update your browser for more security, comfort and the best experience on this site.

Achaogen, Inc.

Achaogen is a clinical-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant (MDR), gram-negative infections.

7000 Shoreline Court, Suite 371, San Francisco, CA 94080, United States

Profile Navigation
This is a community generated profile. If you would like to claim it, please contact us.

About

Our Company

The Centers for Disease Control and Prevention (CDC) characterized carbapenem-resistant Enterobacteriaceae (CRE) as “nightmare bacteria” and an immediate public health threat that requires “urgent and aggressive action”.

Achaogen is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including CRE.

Our research and development pipeline includes additional gram-negative programs such as inhibitors of LpxC, an enzyme essential for the synthesis of the outer membrane of gram-negative bacteria, and a therapeutic antibody program.

Markets

areas of proficiency

Company Type

Choose Company Type

Cancel

Company Size

< 10

Choose Company Size

Cancel

Contact Info

get in touch

  • Location:

    Other: 7000 Shoreline Court, Suite 371, San Francisco, CA 94080, United States